BR112021017604A2 - Compostos úteis na terapia para hiv - Google Patents

Compostos úteis na terapia para hiv

Info

Publication number
BR112021017604A2
BR112021017604A2 BR112021017604A BR112021017604A BR112021017604A2 BR 112021017604 A2 BR112021017604 A2 BR 112021017604A2 BR 112021017604 A BR112021017604 A BR 112021017604A BR 112021017604 A BR112021017604 A BR 112021017604A BR 112021017604 A2 BR112021017604 A2 BR 112021017604A2
Authority
BR
Brazil
Prior art keywords
compounds useful
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
BR112021017604A
Other languages
English (en)
Inventor
Narasimhulu Naidu B
David Temelkoff
Johann Velthuisen Emile
F Miller John
Alicia De La Rosa Martha
Vicente Samano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd, Viiv Healthcare Co filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112021017604A2 publication Critical patent/BR112021017604A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

compostos úteis na terapia para hiv. a presente invenção refere-se a compostos de fórmula (i), seus sais, composições farmacêuticas dos mesmos, bem como métodos de tratamento ou prevenção de hiv em indivíduos.
BR112021017604A 2019-03-06 2020-03-04 Compostos úteis na terapia para hiv BR112021017604A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
BR112021017604A2 true BR112021017604A2 (pt) 2021-11-16

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017604A BR112021017604A2 (pt) 2019-03-06 2020-03-04 Compostos úteis na terapia para hiv

Country Status (21)

Country Link
US (3) US20230174534A1 (pt)
EP (1) EP3934760A1 (pt)
JP (1) JP2022525013A (pt)
KR (1) KR20210136052A (pt)
CN (1) CN113811360A (pt)
AR (1) AR118240A1 (pt)
AU (1) AU2020231934B2 (pt)
BR (1) BR112021017604A2 (pt)
CA (1) CA3132112A1 (pt)
CL (1) CL2021002309A1 (pt)
CO (1) CO2021012579A2 (pt)
CR (1) CR20210460A (pt)
EA (1) EA202192433A1 (pt)
IL (1) IL285894A (pt)
MA (1) MA55200A (pt)
MX (1) MX2021010700A (pt)
PE (1) PE20212089A1 (pt)
SG (1) SG11202109253SA (pt)
TW (1) TW202102233A (pt)
WO (1) WO2020178767A1 (pt)
ZA (1) ZA202106096B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164528A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CN117964624A (zh) * 2020-12-30 2024-05-03 南方科技大学 一种具有治疗病毒感染功效的核苷类化合物及其用途
CA3204255A1 (en) * 2021-01-25 2022-07-28 Lianhong Xu Combination therapy for hiv with adenosine derivative and capsid inhibitors
EP4298105A1 (en) * 2021-02-23 2024-01-03 VIIV Healthcare Company Compounds useful in hiv treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CN1533390A (zh) 2001-03-19 2004-09-29 СҰҩƷ��ҵ��ʽ���� 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170313735A1 (en) * 2014-10-31 2017-11-02 Sandoz Ag Improved Fluorination Process
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2018085307A1 (en) * 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物

Also Published As

Publication number Publication date
US20220411425A1 (en) 2022-12-29
CO2021012579A2 (es) 2021-10-20
MX2021010700A (es) 2021-10-01
MA55200A (fr) 2022-01-12
AU2020231934A8 (en) 2022-03-24
EA202192433A1 (ru) 2021-12-28
TW202102233A (zh) 2021-01-16
WO2020178767A1 (en) 2020-09-10
PE20212089A1 (es) 2021-11-04
AU2020231934B2 (en) 2023-04-20
US20240182473A1 (en) 2024-06-06
CL2021002309A1 (es) 2022-09-20
CR20210460A (es) 2022-02-03
SG11202109253SA (en) 2021-09-29
ZA202106096B (en) 2023-03-29
KR20210136052A (ko) 2021-11-16
CN113811360A (zh) 2021-12-17
JP2022525013A (ja) 2022-05-11
CA3132112A1 (en) 2020-09-10
US20230174534A1 (en) 2023-06-08
IL285894A (en) 2021-10-31
AR118240A1 (es) 2021-09-22
EP3934760A1 (en) 2022-01-12
AU2020231934A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
BR112021017604A2 (pt) Compostos úteis na terapia para hiv
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
BR112017002970A2 (pt) novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112018000635A2 (pt) compostos aza substituídos como inibidores irak-4
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
BR112018071216A2 (pt) inibidores de bromodomínios
BR112015028873A2 (pt) heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112014027236A2 (pt) pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas
BR112017020837A2 (pt) compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
BR112015028538A2 (pt) derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112015014714A2 (pt) compostos carbamoilpiridona policíclicos e seu uso farmacêutico
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112014008686A2 (pt) derivados de oxazina e uso dos mesmos no tratamento de doença
BR112015027055A8 (pt) bi-heteroarilas, usos das mesmas, e composição farmacêutica
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112015018547A2 (pt) microbiocidas
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih